Novartis AG - ADR

NVS

$101.14

+37.4% last 12 months

PRIMECAP Management Holding value: $1.52 Billion Jim Simons Holding value: $238 Million Steven Cohen Holding value: $91.7 Million Ken Fisher Holding value: $87.4 Million Jeremy Grantham Holding value: $69.1 Million Tweedy Browne Holding value: $9.72 Million Ken Griffin Holding value: $168 Thousand John W. Rogers Jr. Holding value: $0 First Eagle Investments Holding value: $0 Mario Gabelli Holding value: $0 Tom Gayner Holding value: $0 Tom Russo Holding value: $0 Chris Davis Holding value: $0

Market Cap

$233 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$71.00 - $105.61

The lowest and highest price in the last 52 weeks.

Price-Earnings Ratio

30.4x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$3.50 (3.43%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Compare to
Market
Industry
Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares. $233 Billion
Enterprise Value A measure of a company's total value. This includes market cap, cash, and debt. $250 Billion
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price. $3.50 (3.43%)
1 Year Return Profit or loss of share price change plus dividend yield. +40.8%
52-Week High Highest share price in the last 52 weeks. $105.61
52-Week Low Lowest share price in the last 52 weeks. $71.00
Beta Beta indicates the volatility of a stock compared to the market. Higher beta means more volatile and thus potentially higher risk and return. 0.35
Outstanding Shares The number of shares the company has issued and are held by stockholders. 2.28 Billion
Avg 30 Day Volume The number of shares traded in the last 30 days. 1.02 Million

Valuation

Compare to
Market
Industry
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. 30.4
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued. 82.8
Earnings per Share Earnings divided by outstanding shares. Higher EPS indicates greater value. $3.58
Price to Sales Ratio Market cap divided by the revenue in the most recent year. 4.4
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company 4.6
Enterprise Value to Revenue Enterprise value divided by revenue 4.7
Enterprise Value to EBIT Enterprise Value divided by EBIT 20.59
Total Debt to Enterprise Value Total debt divided by enterprise value 0.11
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary. 0.55

Profitability

Compare to
Market
Industry
Revenue Revenue is the sum of all cash flow into the company. $53.1 Billion
Gross Profit Gross profit is the profit after subtracting the costs of making and selling its products or the costs of providing its services. It indicates the efficiency of using their resources to produce goods or services. $36.9 Billion
EBIT Earnings before tax and interest payments. $12.1 Billion
Net Income Net Income is the profit after all expenses have been deducted from the total revenue. $7.65 Billion
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability. 14.41%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago. +36.7%
Return on Equity Equity divided by market cap. 14.75%
Return on Assets Indicates a company's profitability in relation to its total assets. 6.89%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. 15.33%

Insider trades

No purchases

No sells

No purchases

No sells

No purchases

No sells

No purchases

No sells

Q4 2022 Q1 2023 Q2 2023 Q3 2023

About Novartis AG - ADR

CEO: Vasant Narasimhan

Industry: Pharmaceuticals: Major

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Similar stocks

Merck & Co Inc
Merck & Co Inc
Pfizer Inc.
Pfizer Inc.
Johnson & Johnson
Johnson & Johnson
Sanofi - ADR
Sanofi - ADR
GSK Plc - ADR
GSK Plc - ADR
Teva- Pharmaceutical Industries Ltd. - ADR
Teva- Pharmaceutical Industries Ltd. - ADR
Abbott Laboratories
Abbott Laboratories
Bayer AG - ADR
Bayer AG - ADR
Astrazeneca plc - ADR
Astrazeneca plc - ADR

News

Novartis'' Phase III NETTER-2 Trial Meets Primary Goal

Novartis'' Phase III NETTER-2 Trial Meets Primary Goal

BASEL (dpa-AFX) - Novartis AG (NVS) on Monday said its NETTER-2 Phase 3 study met its primary goal of improvement in progression-free survival (PFS) in SSTR-...

Finanz Nachrichten Finanz Nachrichten, about 8 hours ago
Prothena: Switching From ''Hold'' To ''Buy'' On Lead Alzheimer''s Drug Promise

Prothena: Switching From ''Hold'' To ''Buy'' On Lead Alzheimer''s Drug Promise

Prothena has lucrative development partnerships with Roche, Novartis, and Bristol Myers Squibb. Click here to see why I am upgrading PRTA stock from Hold to ...

Seeking Alpha Seeking Alpha, 4 days ago
Novartis: fin de l''accord de collaboration avec BeiGene

Novartis: fin de l''accord de collaboration avec BeiGene

(CercleFinance.com) - Novartis et BeiGene ont convenu de mettre fin à leur accord de collaboration et de licence pour le tislelizumab, un anticorps monoclona...

Boursorama Boursorama, 5 days ago
Novartis Pharma AG: Sandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab

Novartis Pharma AG: Sandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab

Positive CHMP opinion based on comprehensive package of analytical, pre-clinical and clinical data Breast and gastric cancers are among most common types of ...

Finanz Nachrichten Finanz Nachrichten, 7 days ago
Never miss a trade
To improve your user experience we use cookies.